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Purpose. Extrapulmonary small cell carcinoma aﬀecting the anal canal is a rare and poorly understood entity which can, in its
early stages, masquerade as benign anorectal disease such as hemorrhoids. Methods. We report a case of this rare malignancy
which initially presented with hematochezia and anal pain. We also review the literature with regard to previously described cases
and management strategies including the role of surgery. Results. Despite aggressive multidisciplinary treatment consisting of
chemotherapy and radiation, the disease progressed rapidly with dissemination occurring only three months after completion of
treatment. Because of the aggressive nature of this tumor, the treatment options for this almost universally fatal malignancy are
often palliative in nature. Conclusion. Chemoradiotherapy is likely the most reasonable approach to extrapulmonary small cell
carcinoma of the anal canal given its aggressiveness.
1.Introduction
Anal carcinomas represent approximately 4% of all gas-
trointestinal cancers diagnosed annually in the United States
with an estimated 5260 new cases to be found in 2010 [1].
Of those, the majority are squamous carcinomas for which
the treatment is well established and the prognosis usually
favorable [2]. Extrapulmonary small cell carcinoma can also
arise in the anal canal. Although it is rare, it is an important
clinical entity due to its aggressive course and lack of well-
deﬁned and standardized treatment. Here we report a case
of small cell carcinoma of the anal canal including our
management and a review of the literature.
2.CaseReport
A 63-year-old female developed episodic hematochezia
and anal pain. Initial anorectal exam revealed only small
internal hemorrhoids and colonoscopy demonstrated no
proximal pathology. Weeks later she developed an enlarged,
symptomatic right inguinal lymph node which was excised
and revealed metastatic small cell carcinoma. She was then
referred to us for evaluation. At this time digital exam
revealed a 2cm ﬁxed mass in the anal canal at the level of
the dentate line. Biopsy of the anal canal mass demonstrated
small cell carcinoma which was histologically similar to that
seen in the inguinal node (Figure 1).
Staging CT of the chest, abdomen, and pelvis, and MRI
of the brain did not reveal distant metastatic disease nor
a primary lung tumor. 18F-FDG PET scan demonstrated
uptake in the anal canal and right inguinal region (Figure 2).
Routine laboratory parameters were normal and serology
was negative for HIV infection. She was treated with
chemoradiotherapy consisting of cisplatin and etoposide
concurrent with radiation therapy during cycles 2 and 3.
She received a total dose of 54Gy in 27 fractions to the2 Case Reports in Medicine
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Figure 1: Histologic section of the inguinal lymph node (a) and anal canal lesion (b) demonstrating small to intermediate malignant cells
with little cytoplasm, nuclear molding, necrosis, and apoptosis. Both showed positive immunoreactivity for keratin AE1/3, synaptophysin
and were negative for p63 (H&E 400x).
(a) (b)
Figure 2: PET scan showing uptake in right inguinal region (a) and anal canal (b).
gross anal tumor and the right inguinal region and 47Gy
in 27 fractions to the pelvis. Intensity-modulated radiation
therapy was used.
Her anal symptoms improved markedly during the ﬁrst
few weeks of treatment. Clinical examination four weeks
after completion of chemoradiotherapy revealed complete
regression of the anal tumor and no palpable recurrence
in the inguinal regions. However, three months after the
completion of chemoradiotherapy, she developed new onset
arm weakness. Imaging revealed the development of exten-
sive brain and intra-abdominal metastasis. Pancreas, adrenal
gland, liver, breast, lung, brain, and lymph nodes all showed
evidence of disease on imaging (Figure 3). At this point,
after multiple discussions with the patient and family,
we proceeded with palliative measures and she ultimately
expired 10 months after the diagnosis was made.
3. Discussion
Small cell lung carcinoma comprises about 13% of all
lung cancers [3]. Histologically identical neoplasms foundCase Reports in Medicine 3
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Figure 3: Metastatic disease: (clockwise starting from upper left) left axillary lymph node, pancreatic lesions, multiple brain metastases, and
right superior perinephric mass.
outside of the lung and with no evidence of pulmonary
involvement are termed extrapulmonary small cell carci-
nomas (EPSCCs). Regardless of where it occurs, EPSCC is
rare and has a reported incidence in the US of 0.1 to 0.4%
[4]. Approximately 650 cases of gastrointestinal EPSCC have
been reported in the literature and the majority of these
have been located in the esophagus, colon, and rectum [5].
Colorectal EPSCC is thought to occur with an incidence of
<1% of all colorectal malignancies [6]. In fact, a review of 50
years of malignant colorectal pathology at the Mayo Clinic
found the incidence of EPSCC to be 2 per 1000 malignant
lesions of the bowel [7].
Small cell carcinoma of the anal canal is extremely
rare and its true incidence is not entirely known; most
of the literature on this topic is in the form of isolated
case reports. Additionally, the existing literature may be
misleading because some reports detailing cases of small
cell carcinoma aﬀecting the rectum might have actually
been describing lesions that arose in the anal canal if
strict deﬁnitions of the surgical anal canal were used. The
largest number of cases was reported by Boman et al.; their
retrospective review of 188 cases of anal canal carcinomas
seen over a 27-year period found that only 13 of them
were actually small cell carcinoma [8]. Table 1 lists the case
reports and series of anal canal EPSCC reported in the
English literature where speciﬁc information with regard to
treatment and outcome was provided.
Because of the rarity of EPSCC, not much is known
about its origin. Some reports refer to these carcinomas
as “neuroendocrine,” but others feel that this terminology
implies anembryologic origin that,as ofyet,is still unproven
[13]. Nonetheless, three theories have been purported to
explain the origins of EPSCC: enteric neuroendocrine cells
derived from the neural crest, pluripotent stem cells derived
fromendoderm,orfromcellsthatsimplyariseoutofnormal
organ-speciﬁc cancers when certain clones reach the end
stages of genetic change [14–17]. The exact histogenesis is
controversial; however, the second and third theories seem
attractive because they provide a reason for why EPSCC of
the GI tract often contains various degrees of other epithelial
cell types [18]. For example, many reports of EPSCC arising
throughout the GI tract describe the lesions occurring next
to or within adenomas [18, 19].
Itisnotknownifanyacquiredorlife-style-relatedfactors
predispose to the development of EPSCC. Although our
patient was a long-time smoker and smoking is frequently4 Case Reports in Medicine
Table 1: Summary of reported cases of anal canal EPSCC.
Author (yr) n Demographic
Metastatic
disease at
presentation
Treatment Clinical course
Alcindor et al. (2008)
[9] 1 45y M HIV+ y Chemoradiation,
C/E, G-CSF
Primary responded, distant disease
progressed, died 6mo after dx
Doddi et al. (2009)
[10] 1 60y F n Chemoradiation,
C/E
Primary responded, distant disease
developed, died 18mo after dx
Nakahara et al. (1993)
[11] 1 48y M HIV+ n
radiation, APR,
chemoradiation,
C/E, G-CSF
Pelvic local recurrence after surgery,
distant disease developed, patient
committed suicide 3mo after surgery
Meyer et al. (2007)
[12] 1 41y F y Chemoradiation,
C/E
Partial response of primary, complete
response of liver and lung metastasis, but
new bone metastasis developed, died
10mo after dx
Boman et al. (1983)
[8]
13 ns
5y ns Median survival 2mo after dx
8n 7A P R
6 patients recurred and had median
survival of 6mo after surgery 1 patient
with 5yr survival
1 radiation Died 8mo after treatment
Ns: not speciﬁed; APR: abdominoperineal resection; C/E: cisplatin and etoposide; G-CSF: granulocyte colony stimulating factor.
associated with SCLC, approximately 30% of patients with
EPSCC are nonsmokers [20]. While radiation has been
implicated in SCLC and there is a case report of a rectal
EPSCC developing in a patient 12 years after pelvic radiation
for a gynecologic malignancy, an association with EPSCC is
not proven [21, 22]. We know that the immune suppression
resulting from HIV infection and AIDS can increase the
risk of developing anal squamous carcinoma. Although
our patient was HIV negative, some of the previous case
reports of anal EPSCC occurred in HIV-infected individuals
(Table 1) thus causing speculation as to the role of this
infectioninthedevelopmentofthisrarecancer[9,11].Given
the small number of patients it is impossible to know if there
is an association.
As highlighted by our case, the initial staging workup
for suspected EPSCC consists of imaging the brain, chest,
abdomen, and pelvis to rule out the lung as the primary and
assessfordistantorlocoregionaldisease.Giventhelymphatic
drainage of the anal canal, if this is the primary location
special attention must be paid to the inguinal lymph nodes.
Suspicious lymphadenopathy not amenable to biopsy should
be further investigated via PET scan as they are typically PET
avid. Since our case presented with locoregional disease only,
weproceededwithtreatmentsimilartothatwhichisdonefor
limited stage SCLC where the typical regimen is concurrent
chemoradiotherapy using cisplatin and etoposide. Although
the patient’s anal symptoms improved drastically and the
primary tumor appeared to have completely regressed by
4 weeks after chemoradiotherapy, signiﬁcant distant disease
arose shortly thereafter.
Unfortunately,nowell-studiedtreatmentguidelinesexist
for anal EPSCC; thus our current strategy relies on how it
is treated when it occurs in other anatomic locations. For
example,Hoskinsetal.foundthatof34patientswithEPSCC
of the cervix treated with chemoradiotherapy, 55% were
long-term survivors [23]. Although there are few patients
reported on in the literature, it seems that this result has not
been duplicated in cases of anal EPSCC. Of those that have
been treated with chemoradiotherapy, most have had at least
an initial response to treatment but, as in our case, this was
quickly followed by emergence of disease in other locations
(Table 1)[ 9, 10, 12]. An explanation for this phenomenon,
as outlined by Brenner et al. might lay in the fact that
these tumors often contain an admixture of squamous or
adenocarcinoma; when the lung-type therapy is used, the
subsequent recurrence might be due to the proliferation of
nonsmall cell clones [17].
Surgery has been employed in cases of anal EPSCC
but the results have been equally disappointing. It did not
signiﬁcantly impact the progression of disease in the case
reported by Nakahara et al. [11]. Moreover, of the 7 anal
canal EPSCC patients treated with APR in the largest report,
six developed recurrence at a median interval of 4 months
fromsurgeryanddied ofdisease roughly2months thereafter
[8]. The authors felt that surgery was a “gross failure”
[8]. However, one of the seven did survive more than 5
years without recurrence and this was the only patient in
their series where the tumor was pathologically determined
to be “conﬁned to the anal epithelium and subepithelial
connective tissue” [8]. By extrapolation it seems that this
would be a T1 tumor by today’s standards. Based on this
single case the question that is raised is as follows: should
a patient with an anal canal EPSCC determined by EUS to be
T1 and by imaging to have no distant metastatic disease be
oﬀered radical resection in the form of APR? There simply is
not enough evidence to guide decision but it is possible that
this is the only scenario in which surgery can oﬀer more than
palliation alone.Case Reports in Medicine 5
4. Conclusion
EPSCC of the anal canal is rare, and in its early stages
may have a clinical presentation similar to other routine
anorectal problems. It continues to be associated with a
very poor prognosis, and at this point, treatment with
chemoradiotherapy seems to be the most reasonable. The
rapid distant dissemination occurring in our patient despite
treatment highlights the fact that this disease is very aggres-
sive and further investigation must be done to deﬁne novel
therapeutic options.
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